CervoMed Inc.

CRVO | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.43

+$0.02 (+0.83%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.83%

(1D)

Rating

Updated: Aug 31, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $22.5M

1D Range

2.42 2.45

52W Range

2.13 10

Valuation (TTM)

PE -0.75

PB 0.97

EV/EBITDA 0.09

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $7

Cash Flow

FCF Yield -125.4%

SBC Adj. FCF Yield -129.9%

SBC Impact -3.6%

Margins

Gross Margin 100.0%

Operating Margin -9661.4%

FCF Margin -8673.4%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | 100.0%

Dil EPS 3Y | 5Y -27.9% | 52.0%

FCF 3Y | 5Y -67.2% | -35.8%

Returns

ROA -116.8%

ROE -156.0%

ROIC -135.7%

Financial Health

Net Cash

$24.94M

Current Ratio 8.57

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an o...

Sector Healthcare

Industry Biotechnology

Employees 15

IPO Date May 22, 2008

Website www.cervomed.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+188.07%

Buy (5)

Hold (0)

Sell (0)

Analyst Details ➞